Role of vandetanib in the management of medullary thyroid cancer

Maryse Brassard1*, Genevi&egrave;ve Rondeau2* 1Endocrinology Service, Department of Medicine, Centre Hospitalier Universitaire Affili&eacute; (CHA), Laval University, Quebec, Canada; 2Endocrinology Service, Department of Medicine, Centre Hospitalier de l&#39;Universit&amp...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rondeau G, Brassard M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/8a1cb82278914d66825eb5c87a2725f9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8a1cb82278914d66825eb5c87a2725f9
record_format	dspace
spelling	oai:doaj.org-article:8a1cb82278914d66825eb5c87a2725f92021-12-02T04:49:38ZRole of vandetanib in the management of medullary thyroid cancer1177-54751177-5491https://doaj.org/article/8a1cb82278914d66825eb5c87a2725f92012-03-01T00:00:00Zhttp://www.dovepress.com/role-of-vandetanib-in-the-management-of-medullary-thyroid-cancer-a9440https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Maryse Brassard1, Genevi&egrave;ve Rondeau2 1Endocrinology Service, Department of Medicine, Centre Hospitalier Universitaire Affili&eacute; (CHA), Laval University, Quebec, Canada; 2Endocrinology Service, Department of Medicine, Centre Hospitalier de l&#39;Universit&eacute; de Montr&eacute;al (CHUM), University of Montreal, Montreal, Canada*Both authors contributed equally to this articleAbstract: Traditionally available treatments, like cytotoxic chemotherapy and external-beam radiation therapy, are limited and essentially ineffective for metastatic medullary thyroid carcinoma (MTC). In the last decade, small-molecule tyrosine kinase inhibitors (TKI) have been introduced in the field of thyroid cancer, after having been shown effective in a wide variety of other tumors. This review focuses on vandetanib (ZD6474, ZactimaTM; AstraZeneca) and its role in the treatment of MTC. Vandetanib is an oral TKI that targets VEGF receptors 2 and 3, RET, and at higher concentrations, the epidermal growth factor (EGF) receptor. This drug has been tested in two important phase II studies which demonstrated that both the 100 and 300 mg/day dosage of vandetanib have antitumor activity on advanced MTC. A phase III trial (ZETA trial) evaluating vandetanib in 331 patients with locally advanced or metastatic MTC showed a significant prolongation of PFS for patients receiving vandetanib compared with placebo. Toxicity surveillance in all studies reported high rates of adverse effects with diarrhea, rash, fatigue and nausea being the most commonly experienced by patients. Vandetanib is currently approved in the United States for unresectable locally advanced or metastatic MTC and has become a new standard of care in this rare and indolent pathology.Keywords: vandetanib, medullary thyroid cancer, RET mutation, VEFGRRondeau GBrassard MDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2012, Iss default, Pp 59-66 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Rondeau G Brassard M Role of vandetanib in the management of medullary thyroid cancer
description	Maryse Brassard1, Genevi&egrave;ve Rondeau2 1Endocrinology Service, Department of Medicine, Centre Hospitalier Universitaire Affili&eacute; (CHA), Laval University, Quebec, Canada; 2Endocrinology Service, Department of Medicine, Centre Hospitalier de l&#39;Universit&eacute; de Montr&eacute;al (CHUM), University of Montreal, Montreal, Canada*Both authors contributed equally to this articleAbstract: Traditionally available treatments, like cytotoxic chemotherapy and external-beam radiation therapy, are limited and essentially ineffective for metastatic medullary thyroid carcinoma (MTC). In the last decade, small-molecule tyrosine kinase inhibitors (TKI) have been introduced in the field of thyroid cancer, after having been shown effective in a wide variety of other tumors. This review focuses on vandetanib (ZD6474, ZactimaTM; AstraZeneca) and its role in the treatment of MTC. Vandetanib is an oral TKI that targets VEGF receptors 2 and 3, RET, and at higher concentrations, the epidermal growth factor (EGF) receptor. This drug has been tested in two important phase II studies which demonstrated that both the 100 and 300 mg/day dosage of vandetanib have antitumor activity on advanced MTC. A phase III trial (ZETA trial) evaluating vandetanib in 331 patients with locally advanced or metastatic MTC showed a significant prolongation of PFS for patients receiving vandetanib compared with placebo. Toxicity surveillance in all studies reported high rates of adverse effects with diarrhea, rash, fatigue and nausea being the most commonly experienced by patients. Vandetanib is currently approved in the United States for unresectable locally advanced or metastatic MTC and has become a new standard of care in this rare and indolent pathology.Keywords: vandetanib, medullary thyroid cancer, RET mutation, VEFGR
format	article
author	Rondeau G Brassard M
author_facet	Rondeau G Brassard M
author_sort	Rondeau G
title	Role of vandetanib in the management of medullary thyroid cancer
title_short	Role of vandetanib in the management of medullary thyroid cancer
title_full	Role of vandetanib in the management of medullary thyroid cancer
title_fullStr	Role of vandetanib in the management of medullary thyroid cancer
title_full_unstemmed	Role of vandetanib in the management of medullary thyroid cancer
title_sort	role of vandetanib in the management of medullary thyroid cancer
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/8a1cb82278914d66825eb5c87a2725f9
work_keys_str_mv	AT rondeaug roleofvandetanibinthemanagementofmedullarythyroidcancer AT brassardm roleofvandetanibinthemanagementofmedullarythyroidcancer
_version_	1718401020437987328

Role of vandetanib in the management of medullary thyroid cancer

Ejemplares similares